Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: Correlation to cell proliferation, tumor size and metabolic syndrome

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 2, 2014, Pages 169-183

  Mollbrink, A ^a   Jawad, R ^a   Vlamis Gardikas, A ^b   Edenvik, P ^a   Isaksson, B ^a   Danielsson, O ^a   Stal P ^a   Fernandes, Aristi ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF PATRAS   (Greece)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Glutaredoxin; Hepatocellular carcinoma; Immunohistochemistry; Thioredoxin

Indexed keywords

GLUTAREDOXIN; GLUTAREDOXIN 2A; GLUTAREDOXIN 2B; GLUTAREDOXIN 2C; GLUTAREDOXIN 3; GLUTAREDOXIN 5; MESSENGER RNA; PARAFFIN; THIOREDOXIN; THIOREDOXIN 1; THIOREDOXIN 2; UNCLASSIFIED DRUG; ALCOHOL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER MORPHOLOGY; CANCER SIZE; CANCER SURGERY; CANCER TISSUE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOSOL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; MALE; METABOLIC SYNDROME X; MITOCHONDRION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SMOKING; TUMOR INVASION; ANTHROPOMETRY; CANCER CHEMOTHERAPY; CANCER PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; PREOPERATIVE TREATMENT; SEX DIFFERENCE; SEX RATIO; TOBACCO CONSUMPTION; TUMOR VOLUME; UPREGULATION;

AGED; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; GLUTAREDOXINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PARAFFIN EMBEDDING; PROGNOSIS; RISK FACTORS; RNA, MESSENGER; THIOREDOXINS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84907367977     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700204     Document Type: Article

References (32)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-76. (Pubitemid 46890874)
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-36. (Pubitemid 43112690)
3. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 2013; 87:227-47.
4. Kawahara N, Tanaka T, Yokomizo A, et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 1996; 56:5330-3. (Pubitemid 27011357)
5. Fernandes AP, Holmgren A. Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid Redox Signal 2004; 6:63-74. (Pubitemid 38063976)
6. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000; 29:312-22.
7. Zhu X, Huang C, Peng B. Overexpression of thioredoxin system proteins predicts poor prognosis in patients with squamous cell carcinoma of the tongue. Oral Oncol 2011; 47:609-14.
8. Lim JY, Yoon SO, Hong SW, Kim JW, Choi SH, Cho JY. Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence. World J Gastroenterol 2012; 18:5581-8.
9. Grogan TM, Fenoglio-Prieser C, Zeheb R, et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 2000; 31:475-81. (Pubitemid 30262870)
10. Nagano M, Hatakeyama K, Kai M, Nakamura H, Yodoi J, Asada Y, Chijiiwa K. Nuclear expression of thioredoxin-1 in the invasion front is associated with outcome in patients with gallbladder carcinoma. HPB (Oxford) 2012; 14:573-82.
11. Kakolyris S, Giatromanolaki A, Koukourakis M, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001; 7:3087-91. (Pubitemid 32963828)
12. Noike T, Miwa S, Soeda J, Kobayashi A, Miyagawa S. Increased expression of thioredoxin-1, vascular endothelial growth factor, and redox factor-1 is associated with poor prognosis in patients with liver metastasis from colorectal cancer. Hum Pathol 2008; 39:201-8.
13. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006; 97:813-20. (Pubitemid 44151259)
14. Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin Cancer Res 1996; 2:427-32. (Pubitemid 26074625)
15. Lillig CH, Lonn ME, Enoksson M, Fernandes AP, Holmgren A. Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide. Proc Natl Acad Sci U S A 2004; 101:13227-32. (Pubitemid 39209647)
16. Cunnea P, Fernandes AP, Capitanio A, Eken S, Spyrou G, Bjornstedt M. Increased expression of specific thioredoxin family proteins; a pilot immunohistochemical study on human hepatocellular carcinoma. Int J Immunopathol Pharmacol 2007; 20:17-24. (Pubitemid 46506872)
17. Corona G, De Lorenzo E, Elia C, et al. Differential proteomic analysis of hepatocellular carcinoma. Int J Oncol 2010; 36:93-9.
18. Prasad H, Ryan DA, Celzo MF, Stapleton D. Metabolic syndrome: definition and therapeutic implications. Postgrad Med 2012; 124:21-30.
19. Lillig CH, Berndt C, Vergnolle O, Lonn ME, Hudemann C, Bill E, Holmgren A. Characterization of human glutaredoxin 2 as iron-sulfur protein: a possible role as redox sensor. Proc Natl Acad Sci U S A 2005; 102:8168-73. (Pubitemid 40800061)
20. Potamitou A, Holmgren A, Vlamis-Gardikas A. Protein levels of Escherichia coli thioredoxins and glutaredoxins and their relation to null mutants, growth phase, and function. J Biol Chem 2002; 277:18561-7. (Pubitemid 34952407)
21. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997; 45:1559-65. (Pubitemid 27465476)
22. Arodin L, Lamparter H, Karlsson H, Nennesmo I, Bjornstedt M, Schroder J, Fernandes AP. Alteration of Thioredoxin and Glutaredoxin in the progression of Alzheimer's disease. J Alzheimers Dis 2014; 39(4):787-97.
23. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 2010; 396:120-24.
24. Lillig CH, Berndt C, Holmgren A. Glutaredoxin systems. Biochim Biophys Acta 2008; 1780:1304-17.
25. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003; 38:32-8. (Pubitemid 36078521)
26. Wu H, Lin L, Giblin F, Ho YS, Lou MF. Glutaredoxin 2 knockout increases sensitivity to oxidative stress in mouse lens epithelial cells. Free Rad Biol Med 2011; 51:2108-17.
27. Mailloux RJ, Xuan JY, Beauchamp B, Jui L, Lou M, Harper ME. Glutaredoxin-2 is required to control proton leak through uncoupling protein-3. J Biolog Chem 2013; 288:8365-79.
28. Tanaka T, Hosoi F, Yamaguchi-Iwai Y, et al. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J 2002; 21:1695-703. (Pubitemid 34614625)
29. Perez VI, Lew CM, Cortez LA, et al. Thioredoxin 2 haploinsufficiency in mice results in impaired mitochondrial function and increased oxidative stress. Free radical biology & medicine 2008; 44:882-92.
30. He M, Cai J, Go YM, Johnson JM, Martin WD, Hansen JM, Jones DP. Identification of thioredoxin-2 as a regulator of the mitochondrial permeability transition. Toxicol Sci 2008; 105:44-50.
31. Zhou J, Damdimopoulos AE, Spyrou G, Brune B. Thioredoxin 1 and thioredoxin 2 have opposed regulatory functions on hypoxia-inducible factor-1 alpha. J Biolog Chem 2007; 282:7482-90. (Pubitemid 47093694)
32. Soini Y, Kallio JP, Hirvikoski P, et al. Antioxidant enzymes in renal cell carcinoma. Histol Histopathol 2006; 21:157-65. (Pubitemid 43033724)